The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BSH 2017 | Are we ready to use minimal residual disease (MRD) to direct multiple myeloma therapy?
Ola Landgren, MD, PhD, from the Memorial Sloan Kettering Cancer Center, New York, NY, discusses how minimal residual disease (MRD) detection can be used in the clinic for multiple myeloma (MM) at the 2017 British Society for Haematology (BSH) Annual Scientific Meeting in Brighton, UK. He explains how MRD can be used to adjust therapy dosage and determine the response to different treatment. Prof. Landgren also discusses different methods of MRD detection, including new ways to detect MRD in the blood. According to Prof. Landgren, MRD may be more important in determining outcome than the type of therapy given to obtain MRD negativity, and could be used to individualize therapy.
